Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
16 04 2019
Historique:
received: 16 09 2018
accepted: 22 12 2018
pubmed: 19 1 2019
medline: 10 1 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

Artemisinin resistance in falciparum malaria is associated with kelch13 propeller mutations, reduced ring stage parasite killing, and, consequently, slow parasite clearance. We assessed how parasite age affects parasite clearance in artemisinin resistance. Developmental stages of Plasmodium falciparum parasites on blood films performed at hospital admission and their kelch13 genotypes were assessed for 816 patients enrolled in a multinational clinical trial of artemisinin combination therapy. Early changes in parasitemia level (ie, 0-6 hours after admission) were determined mainly by modal stage of asexual parasite development, whereas the subsequent log-linear decline was determined mainly by kelch13 propeller mutations. Older circulating parasites on admission were associated with more-rapid parasite clearance, particularly in kelch13 mutant infections. The geometric mean parasite clearance half-life decreased by 11.6% (95% CI 3.4%-19.1%) in kelch13 wild-type infections and by 30% (95% CI 17.8%-40.4%) in kelch13 mutant infections as the mean age of circulating parasites rose from 3 to 21 hours. Following the start of antimalarial treatment, ongoing parasite sequestration and schizogony both affect initial changes in parasitemia. The greater dependency of parasite clearance half-life on parasite age in artemisinin resistant infections is consistent with ring stage resistance and consequent parasite clearance by sequestration. The stage of parasite development should be incorporated in individual assessments of artemisinin resistance.

Sections du résumé

BACKGROUND
Artemisinin resistance in falciparum malaria is associated with kelch13 propeller mutations, reduced ring stage parasite killing, and, consequently, slow parasite clearance. We assessed how parasite age affects parasite clearance in artemisinin resistance.
METHODS
Developmental stages of Plasmodium falciparum parasites on blood films performed at hospital admission and their kelch13 genotypes were assessed for 816 patients enrolled in a multinational clinical trial of artemisinin combination therapy.
RESULTS
Early changes in parasitemia level (ie, 0-6 hours after admission) were determined mainly by modal stage of asexual parasite development, whereas the subsequent log-linear decline was determined mainly by kelch13 propeller mutations. Older circulating parasites on admission were associated with more-rapid parasite clearance, particularly in kelch13 mutant infections. The geometric mean parasite clearance half-life decreased by 11.6% (95% CI 3.4%-19.1%) in kelch13 wild-type infections and by 30% (95% CI 17.8%-40.4%) in kelch13 mutant infections as the mean age of circulating parasites rose from 3 to 21 hours.
CONCLUSION
Following the start of antimalarial treatment, ongoing parasite sequestration and schizogony both affect initial changes in parasitemia. The greater dependency of parasite clearance half-life on parasite age in artemisinin resistant infections is consistent with ring stage resistance and consequent parasite clearance by sequestration. The stage of parasite development should be incorporated in individual assessments of artemisinin resistance.

Identifiants

pubmed: 30657916
pii: 5290436
doi: 10.1093/infdis/jiy673
pmc: PMC6467186
doi:

Substances chimiques

Antimalarials 0
Artemisinins 0
Protozoan Proteins 0
artemisinin 9RMU91N5K2

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1483-1489

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

J Infect Dis. 2016 Sep 1;214(5):753-61
pubmed: 27252475
Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):436-43
pubmed: 8249075
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):397-402
pubmed: 21173254
J Infect Dis. 1996 Mar;173(3):691-8
pubmed: 8627034
Malar J. 2015 Sep 22;14:359
pubmed: 26390866
Exp Parasitol. 1993 Feb;76(1):85-95
pubmed: 8467901
Malar J. 2017 Feb 23;16(1):88
pubmed: 28231817
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
J Infect Dis. 2015 Jan 15;211(2):290-7
pubmed: 25183768
Lancet Infect Dis. 2013 Dec;13(12):1043-9
pubmed: 24035558
Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):590-7
pubmed: 1287908
Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S41-3
pubmed: 8053024
J Infect Dis. 2002 May 15;185(10):1538-41
pubmed: 11992295
Antimicrob Agents Chemother. 2015 Oct;59(10):6428-36
pubmed: 26239987
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520
pubmed: 28289193
Lancet. 2010 Nov 13;376(9753):1647-57
pubmed: 21062666
PLoS Biol. 2015 Apr 22;13(4):e1002132
pubmed: 25901609
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Malar J. 2011 Nov 10;10:339
pubmed: 22074219
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Malar J. 2008 Apr 11;7:57
pubmed: 18402713
Lancet. 2005 Aug 27-Sep 2;366(9487):717-25
pubmed: 16125588
Antimicrob Agents Chemother. 2015;59(6):3156-67
pubmed: 25779582

Auteurs

Benjamas Intharabut (B)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Hugh W Kingston (HW)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, United Kingdom.

Ketsanee Srinamon (K)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Elizabeth A Ashley (EA)

Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, United Kingdom.
Myanmar Oxford Clinical Research Unit, Yangon, Myanmar.

Mallika Imwong (M)

Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Mehul Dhorda (M)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
WorldWide Antimalarial Resistance Network, Asia Regional Centre, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, United Kingdom.

Charles Woodrow (C)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, United Kingdom.

Kasia Stepniewska (K)

WorldWide Antimalarial Resistance Network, Asia Regional Centre, Bangkok, Thailand.

Kamolrat Silamut (K)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Nicholas P J Day (NPJ)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Arjen M Dondorp (AM)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, United Kingdom.

Nicholas J White (NJ)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH